CymaBay Therapeutics
CBAY
$32.48
Share price
0.00%
Change (1 day)
221.27%
Change (1 year)
Categories
CymaBay Therapeutics (CBAY) - Cash on Hand
Cash on Hand as of December 2023 : $0.39 B
According to CymaBay Therapeutics
's latest financial reports the company has $0.39 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
CymaBay Therapeutics - Cash on Hand chart (from 2013 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-12-31 | $0.39 B | 191% |
| 2022-12-31 | $0.13 B | -27.37% |
| 2021-12-31 | $0.18 B | 27.48% |
| 2020-12-31 | $0.14 B | -23.37% |
| 2019-12-31 | $0.19 B | 6.87% |
| 2018-12-31 | $0.17 B | 83.79% |
| 2017-12-31 | $97.21 M | 472.03% |
| 2016-12-31 | $16.99 M | -59.03% |
| 2015-12-31 | $41.48 M | 19.21% |
| 2014-12-31 | $34.79 M | 11.37% |
| 2013-12-31 | $31.24 M | 304.4% |
| 2012-12-31 | $7.72 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $12.69 B | 3,118.73% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $9.67 B | 2,352.73% | 🇺🇸 USA |
 Xencor XNCR | $0.59 B | 50.59% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | $0.87 B | 122.38% | 🇺🇸 USA |